The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
about
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinaseCrystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loopStructural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitorsThe ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in actionGenetic, molecular and functional analyses of complement factor I deficiencyProtein regions important for plasminogen activation and inactivation of alpha2-antiplasmin in the surface protease Pla of Yersinia pestis.A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.Computer-assisted mutagenesis of ecotin to engineer its secondary binding site for urokinase inhibition.A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.Structural and energetic determinants of the S1-site specificity in serine proteases.Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibilityTargeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodiesReprogramming urokinase into an antibody-recruiting anticancer agent.Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progressionDevelopment of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination.Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environmentDistinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validationA novel mode of intervention with serine protease activity: targeting zymogen activation.Application of molecular modeling to urokinase inhibitors development.Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.Fibrinolytic enzymes from a newly isolated marine bacterium Bacillus subtilis A26: characterization and statistical media optimization.Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.Optimal subsite occupancy and design of a selective inhibitor of urokinase.Converting tissue-type plasminogen activator into a zymogen.Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation.A structural mechanism of flavonoids in inhibiting serine proteases.Identification of allosteric disulfides from labile bonds in X-ray structures.Trimeresurus stejnegeri snake venom plasminogen activator. Site-directed mutagenesis and molecular modeling.Serine proteinase inhibition by the active site titrant N α-(N,N-dimethylcarbamoyl)-α-azaornithine p-nitrophenyl esterMechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1Earthworm ProteaseTherapeutic applications of serine protease inhibitors
P2860
Q27622497-70F6C5BC-EE49-4118-A72B-8D8B7A735D3EQ27634754-8920CACC-291E-4BE0-A35B-9849E5E97D56Q27666429-A7258FDB-A7AC-41D6-9A81-09BB14DABE11Q27742255-88807042-CF3C-453D-8F83-721BE2D0B41CQ27765730-15C5B1D8-FD56-4986-91B0-0AEF0FF6B02FQ28303343-7EF503B6-D3F8-4348-A8A3-129B39208A78Q30168111-1E49ECCB-3BF2-4EA1-A677-EAC8973F7D3DQ30168478-854B2A59-715B-4E7A-A248-27E5CDE63C2BQ30832768-D6F21D6D-A12A-4F26-AFDF-0B67F693E681Q33222784-9E131AC5-2654-4CEA-9E88-CB7C033E8F6EQ33548213-08BF4049-9338-4261-804A-CE80FB1D9773Q33794163-69ECB580-8C07-49CE-83B2-9533CAB9A0CFQ34784373-BEC3FA21-5CE2-4A9A-AA68-C18FAF721D58Q35431906-DC491406-1029-498D-B147-A4D65B7547C3Q35785499-2D53784F-9D17-408B-9F34-928CD264D58CQ35929823-E7C39E5B-4EEC-44DF-91A0-544793B237D6Q36255134-83048047-98F0-452A-B5B9-B7DD6B3D8DD6Q36337574-672CE24A-43B5-4078-9DBC-A2EC30A5649BQ36639269-68719535-EBE4-4B93-8080-B2618E326C8EQ36867219-C28D01DE-317A-483D-861A-B8D4DBAD47A4Q38688610-AD5CFEE9-8195-4977-991F-4E2FEE7D92F3Q39910451-CAD401E3-AF16-4C74-9636-00C3E6CC2110Q40629341-73309828-1EAA-47E1-B3FF-53F5B9F58B3CQ40775925-160DDAD7-5374-4114-A3D8-6855362072D0Q43561321-4B189238-094D-4D59-ADD5-E3374BFBBF08Q43705156-16DD0667-3E65-4669-BC64-CD6A7FBC78E9Q44779601-F471803A-4568-4DC4-B9B5-2AFF79D52655Q45940894-B8BFB45B-72EB-47F3-B1CB-D312265FBAE0Q45968900-6B755FDF-67CB-48A0-882F-24D6399E5A15Q50114294-182D1149-D087-4497-924B-F7545B1C6EA5Q50927462-04C833EB-60EA-478D-BCAE-1C803693170FQ52668129-45572332-E279-40C5-B2F0-E620CA283A84Q54560061-8B742EA8-7257-4BC6-AC0C-6EB7091114CCQ56877679-3ED8D142-F380-487E-A74B-94DB06B64903Q58022615-72C50CA2-AA35-4B9B-90CB-92666493A357Q58650317-6BE445AF-0905-4C5C-8E9F-41CC2379F08CQ58863311-4E17B8AC-6CBE-4813-A987-CE550F074A14
P2860
The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The crystal structure of the c ...... ase-type plasminogen activator
@ast
The crystal structure of the c ...... ase-type plasminogen activator
@en
The crystal structure of the c ...... ase-type plasminogen activator
@nl
type
label
The crystal structure of the c ...... ase-type plasminogen activator
@ast
The crystal structure of the c ...... ase-type plasminogen activator
@en
The crystal structure of the c ...... ase-type plasminogen activator
@nl
prefLabel
The crystal structure of the c ...... ase-type plasminogen activator
@ast
The crystal structure of the c ...... ase-type plasminogen activator
@en
The crystal structure of the c ...... ase-type plasminogen activator
@nl
P2093
P50
P1433
P1476
The crystal structure of the c ...... ase-type plasminogen activator
@en
P2093
C M Dobson
C Phillips
D Saunders
G Spraggon
P304
P356
10.1016/S0969-2126(01)00203-9
P577
1995-07-01T00:00:00Z